In September 2020 the FDA (Food & Drug Administration) published two new medicinal products regulations. These regulations prescribe the minimal good manufacturing practice standards for medical devices to be employed in, and the proper controls and facilities to be utilized for, the production, handling, packaging, and holding of a pharmaceutical product for human ingestion or for use by an animal, to ensure that these medicinal product meets all the needs of the public for safe consumption. These regulations also set standards for the strength, purity, texture, color, solubility, quality control, and storage of pharmaceuticals during transport. The primary components of medicinal products under these regulations include:
This helps to maintain consistency in the treatment of diseases with these medicines. The two main components are the International Nomenclature of Cosmetic Ingredients (INACS) and the U.S. Pharmacopoeia. Both of these regulate the ingredients of medicines to ensure safety.
Food And Drug Administration
The Food and Drug Administration regulates the manufacturing of drugs and their ingredients. This includes all pharmaceuticals, vitamins, and herbal medications. The two medicinal products regulations published by the FDA establish the manufacturing standards for these items under the current good manufacturing practice (CVP) guidelines.
The two regulations 2020 issued by the FDA are important because they establish what medicinal products manufacturers must supply to the healthcare industry. Both of these documents provide the basis for regulating the manufacture of medicines. These two documents describe what must be included on the labeling of medicines and what must be contained in the packaging of such medicines. The two statutory instruments have established timelines for implementation of these regulations.
Manufacturers Of Pharmaceuticals:
There are three main components included in the two medicinal products regulations. The first is the requirement that manufacturers of pharmaceuticals must comply with the specifications listed in the CVP. The second is the submission of an application for authorization to manufacture, package, or label medicinal products. The final component is the regulation of non-compliance with these requirements. This part of the regulations requires manufacturers to submit plans for corrective actions if they become aware of an anticipated non-compliance.
Violation Of The Guidelines
The medical devices and pharmaceuticals manufacturing facilities are inspected by the FDA. Before a facility can start manufacturing, it must submit an application to the FDA for registration and labeling. Manufacturers must also submit reports detailing their manufacturing facility inspection and control activities to the FDA. The facilities need to be inspected every three years or depending on the size of the facility. Facilities that do not submit a report are in violation of the guidelines and are subject to penalty.
One area that the FDA regulates closely is advertising and labeling. The marketing of pharmaceuticals and medical devices can have an impact on the public if the wrong information is provided. Manufacturers are required to provide medical device advertising and labeling that comply with the guidelines. For example, advertising methods must be specific and truthful so that consumers do not become confused or affected by the product. The advertising must be in line with the strength, frequency of use, and contraindications of the product.
Both the qualified person and the manufacturer should act in accordance with the directives for compliance. Manufacturers are expected to follow good manufacturing practice techniques to prevent contamination of drugs during manufacturing and packaging. They are also responsible for maintaining accurate records to track manufacturing process progress. Both the qualified person and the manufacturer should also notify each other of any changes that may affect the strength, frequency of use, and contraindications of the product.